we want to to have open yoidz in formulation that deter abuse.ii believe that's everyone's best interest to find a way tone creant vise that. while at the same time recognizing the impact and importance of the questioner in rick in the u.s. market. accomplishing -- our first action was earlier in the year. we put out the guidance laying out how we would try to increant vise the development of new formulations. following up on that, we're now thinking about ways to develop guidance on abuse deterrent form laces and generic to allow them to come on the market as well. in other places, and in this place i would expect are focus would be on the performance of those generic and not on the technology that was used demonstrate they are use -- the thing we want to have rather than they use their same technology. while recognizing the important role the innovator plays in term of developing new innovative products. >> thank you. recognize the . >> thank you. imha percent of docs what what percent of pain of narcotics? i actually don't know. i know, the in

including recent work we've done to encourage the development of abuse deterrent drug formations for oip yoidz. the fda believes the development of these new formulations to successfully deter abuse is an important part of our efforts to improve their safe use. for example, in january of this year fda issued a draft guidance document for industry outlining the development of abuse deterrent the oip yoid drug products. and in the fall the fda will participate in a public meeting to discuss the issues addressed in that draft guidance as well as issues surrounding the development of abuse deterrent formulations for generic drug products. in addition, the fda has taken recent regulatory actions concerning two opioid products, oxycontin and to panama er charm reformulated with the intention of making the products more difficult to manipulate and abuse. the data for these two products were reviewed carefully and independently by fda scientists and resulted in a change in the labeling for oxycontin. our decisions relied on the totality of the evidence for the or particular drug at hand, and given whe